Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9984759 | 1.00 | P2RX7 (0.41) | P2RX7CYP2D6CYP2C19 | |
| SCHEMBL9984755 | 1.00 | P2RX7 (0.41) | P2RX7CYP2D6CYP2C19 | |
| SCHEMBL19381628 | 0.86 | P2RX7 (0.42) | P2RX7CYP2D6CYP2C19 | |
| SCHEMBL3901853 | 0.84 | P2RX7 (0.41) | P2RX7CYP2D6CYP2C19 | |
| SCHEMBL76783 | 0.84 | P2RX7 (0.41) | P2RX7CYP2D6CYP2C19 | |
| SCHEMBL12191694 | 0.84 | P2RX7 (0.41) | P2RX7CYP2D6CYP2C19 | |
| SCHEMBL5423530 | 0.84 | P2RX7 (0.41) | P2RX7CYP2D6CYP2C19 | |
| SCHEMBL32688678 | 0.84 | P2RX7 (0.41) | P2RX7CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL3901856 | 0.82 | P2RX7 (0.40) | P2RX7CYP2D6CYP2C19 | |
| SCHEMBL7112807 | 0.82 | P2RX7 (0.40) | P2RX7CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585569-A1 | PERFUME SYSTEMS | The Procter and Gamble Company (US) | 2013-05-01 | — | — | EP | claimed |
| WO-2011163337-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2011-12-29 | — | — | WO | claimed |
| US-20110308555-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE COMPANY, THE | 2011-12-22 | — | — | US | claimed |
| US-20200115400-A1 | METHOD FOR PRODUCING SILICON COMPOUND, AND SILICON COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-04-16 | — | — | US | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| EP-3085759-A2 | PERFUME SYSTEMS | The Procter and Gamble Company (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-9326973-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-7838088-B2 | Cyclic olefin-based polymer, and optical material, polarizing plate and liquid crystal display device using the same | FUJIFILM CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-7649118-B2 | Process for preparing fluorine-containing norbornene derivative | DAIKIN INDUSTRIES, LTD. (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20090040436-A1 | Cyclic Olefin-Based Polymer, and Optical Material, Polarizing Plate and Liquid Crystal Display Device Using the Same | FUJIFILM CORPORATION (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090040436-A1 | Cyclic Olefin-Based Polymer, and Optical Material, Polarizing Plate and Liquid Crystal Display Device Using the Same | FUJIFILM CORPORATION (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20080299329-A1 | CYCLIC OLEFIN POLYMER, OPTICAL MATERIAL, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY | FUJIFILM CORPORATION (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080299329-A1 | CYCLIC OLEFIN POLYMER, OPTICAL MATERIAL, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY | FUJIFILM CORPORATION (JP) | 2008-12-04 | — | — | US | disclosed |
| US-7344820-B2 | Chemically amplified polymer having pendant group with dicyclohexyl and resist composition comprising the same | DONGJIN SEMICHEM CO., LTD. (KR) | 2008-03-18 | — | — | US | disclosed |
| US-20070129576-A1 | Process for preparing fluorine-containing norbornene derivative | DAIKIN INDUSTRIES, LTD. | 2007-06-07 | — | — | US | disclosed |
| US-7186773-B2 | Process for preparing fluorine-containing norbornene derivative | DAIKIN INDUSTRIES, LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110308555-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | P2RX7 246/4885CYP2D6 792/4885CYP2C19 354/4885 |
| US-20070129576-A1 | Process for preparing fluorine-containing norbornene derivative | ADH1A, FLNA, FFAR2 | P2RX7 4397/4885CYP2D6 1459/4885CYP2C19 1106/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | P2RX7 4283/4885CYP2D6 2878/4885CYP2C19 4064/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | P2RX7 4283/4885CYP2D6 2878/4885CYP2C19 4064/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | P2RX7 4396/4885CYP2D6 3573/4885CYP2C19 4541/4885 |
| US-20200115400-A1 | METHOD FOR PRODUCING SILICON COMPOUND, AND SILICON COMPOUND | SI, SIK1, CA1 | P2RX7 4866/4885CYP2D6 2112/4885CYP2C19 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.